ライフサイエンスコーパス: remit

1 ileptogenesis with spontaneous seizures that remit.

2 hat could become chronic even after symptoms remit.

3 bit subthreshold symptoms, or go on to fully remit.

4 Unfortunately, most patients fail to remit.

5 e, and Hispanic patients were more likely to remit.

6 follow-up; otherwise, the MDD was considered remitted.

7 en when their seizures are controlled and/or remitted.

8 istory and were present even among those who remitted.

9 , 1.07-7.71]) compared with those whose ADHD remitted.

10 nically isolated syndrome, 29 with relapsing-remitting, 28 with secondary-progressive and 28 with pri

11 versus 49.13 +/- 1.19, P < 0.01), relapsing-remitting (48.86 +/- 2.89 versus 47.44 +/- 2.70, P < 0.0

12 Ten of 11 patients remitted (50% reduction in 24-item Hamilton Depression R

13 ncluded 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive) and 15 he

14 e rs2242446 C/C genotype were more likely to remit (73.1%) than those with either the C/T (51.8%) or

15 ent group, even in patients whose depression remitted acutely according to clinical measures.

16 D group showed under-activation, whereas the remitted ADHD group did not differ significantly from th

17 cording period, spontaneous seizure episodes remit after approximately 4 weeks.

18 adults followed since childhood, contrasting remitted against persistent ADHD.

19 ible participants, 181 (39%) of whom did not remit and were randomly assigned to aripiprazole (n=91)

20 g data were obtained for 36 participants who remitted and 29 who did not respond to treatment.

21 arge vessels (MaxBTP) in comparison with the remitted and control groups.

22 n and Anxiety, including 2,292 patients with remitted and current diagnoses of depressive or anxiety

23 tom severity, a distinction was made between remitted and persistent patients.

24 Forty-three patients with relapsing remitting and 28 with secondary progressive multiple scl

25 ting brain and spinal cord in both relapsing-remitting and progressive forms of MS and may be benefic

26 Individuals suffering from relapsing-remitting and secondary progressive MS had significantly

27 ce from the ventricles in both the relapsing remitting and secondary progressive multiple sclerosis g

28 t remission criteria, 10.0% (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met

29 After treatment, 16 PTSD patients were remitted, and 23 had persistent PTSD based on PTSD diagn

30 ng evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis an

31 ls with at least 1 current SUD at wave 1 who remitted at wave 2 (n = 2741).

32 on (auto-HSCT) has been used successfully to remit autoimmune-mediated neurological diseases.

33 This case of relapsing-remitting AVWS demonstrates the use of VWFpp:Ag for pred

34 Results showed that persons with remitted (B=-52.6) and current (B=-60.8) depressive or a

35 h M. amphoriforme manifesting as a relapsing-remitting bacterial load, interspersed by periods when t

36 in treatment-resistant depression (TRD) and remitted BD.

37 unstructured peer support for patients with remitted bipolar disorder.

38 pletion led to reward-processing deficits in remitted bulimia nervosa, the purpose of this study was

39 ehavioral, and neural responses directly, 17 remitted bulimic (rBN) and 21 healthy individuals (HC) r

40 to suggest that even if distress appears to remit by adulthood, heightened risk of cardiometabolic d

41 By contrast, the ADHD group that remitted by adulthood did not differ significantly from

42 llergic inflammation and that the disease is remitted by disrupting inflammatory and T-helper type 2

43 ), offspring with an episode of MDD that had remitted by follow-up (n = 4), and offspring with missin

44 onally characterized by an initial relapsing-remitting clinical course and focal inflammatory lesions

45 The case is presented due to the relapsing-remitting clinical course of the disease that resulted i

46 matter of the CNS, resulting in a relapsing-remitting CNS autoimmunity.

47 e (coefficient = -0.32, P = 0.03), relapsing-remitting (coefficient = -0.48, P < 0.01), secondary-pro

48 y finding that both drugs increased the time remitted compared with placebo.

49 nfantile liver involvement, and subacute and remitting course simulating multiple sclerosis.

50 Despite varying prior severity of relapsing-remitting course, all participants experienced unexpecte

51 terized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains la

52 Remitted depressed (n=48) and healthy volunteers (n=48)

53 rently depressed individuals, 25 unmedicated remitted depressed individuals, and 30 individuals at hi

54 tients with depression (n=25), patients with remitted depression (n=24) and community controls (n=25)

55 f nicotine dependence among individuals with remitted depression (rMDD).

56 Patients with MS with relapsing-remitting disease course or SP were included.

57 progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2-weighted

58 s more common in younger patients, relapsing-remitting disease course, and after a smaller change in

59 n-reactive CD4 T cells that elicit relapsing-remitting disease have not been quantified.

60 bal increasing incidence driven by relapsing-remitting disease in females.

61 s are based on what is known about relapsing-remitting disease remains unclear.

62 ecause atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control is import

63 elays disease onset of PLP-induced relapsing-remitting disease, reduces relapses and diminishes clini

64 Interestingly, JDM is not a self-remitting disease, suggesting that the high proportion o

65 o was observed in MS patients with relapsing-remitting disease.

66 younger patients and patients with relapsing-remitting disease.

67 at they have a role in chronic relapsing and remitting diseases of both barrier and non-barrier tissu

68 t relapse in a SJL animal model of relapsing-remitting EAE abrogated clinical disease, inflammation,

69 Fc ameliorated clinical relapse in relapsing-remitting EAE.

70 lly, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE

71 ystem Xc(-) attenuates chronic and relapsing-remitting experimental autoimmune encephalomyelitis (EAE

72 ive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomyelitis (EAE

73 , guanabenz ameliorates relapse in relapsing-remitting experimental autoimmune encephalomyelitis.

74 n of alpha-methyl-para-tyrosine (AMPT) in 18 remitted female subjects with BN (rBN) and 31 healthy fe

75 effective in three patients, and one patient remitted following rituximab treatment.

76 ine personality disorder were more likely to remit for a period of 2 years and for a period of 4 year

77 ons can cause an early adult-onset relapsing-remitting form of polyglucosan body disease distinct fro

78 010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syndrome) wit

79 ignificant in both progressive and relapsing-remitting forms of the disease and correlated with WM T2

80 evitably the role of executive nurses, whose remit frequently includes responsibility for quality and

81 Adults who remit from a substance use disorder (SUD) are often thou

82 ADHD symptoms and explain why some children remit from ADHD, whereas others persist.

83 As compared with those who do not remit from an SUD, remitters have less than half the ris

84 at least 1 current SUD at wave 1 who did not remit from any SUDs at wave 2 (n = 3275) and among indiv

85 etween patients who persist versus those who remit from the diagnosis as adults.

86 Individuals who remitted from 1 SUD during this period were significantl

87 garding future rewards, we compared 23 women remitted from AN (RAN group; to reduce the confounding e

88 Women remitted from AN failed to increase activation of reward

89 and two vulnerable populations: individuals remitted from depression and otherwise healthy individua

90 o spent more than 6 months in an institution remitted from markedly higher rates at ages 6 years (p=0

91 the classifier that differentiates relapsing-remitting from progressive MS achieved a validated AUROC

92 show that when a depressed mother's symptoms remit, her children's psychiatric symptoms decrease.

93 autoimmunity, type 1 diabetes and relapsing-remitting immune-mediated demyelination.

94 Common, mild disorders often remit in young adulthood, but more severe disorders can

95 type 2 diabetes at baseline, type 2 diabetes remitted in 66 of 88 patients (75%) at 2 years, in 54 of

96 ransient neonatal diabetes, the diabetes had remitted in only ten (10%) of 101 patients tested early

97 gnetic resonance imaging was conducted in 33 remitted individuals with a history of recurrent major d

98 cies responsible for a chronic relapsing and remitting infection in PAD patients in the United Kingdo

99 's disease (CD) is a lifelong, relapsing and remitting inflammatory condition of the intestine.

100 ltiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central nervous sy

101 The group's remit is to provide expert guidance for the long-term ma

102 The results showed that only BMSCs remitted liver damage and rescued ALF in ConA-treated mi

103 We analyzed data from 80 older adults with remitted major depression (36 with mild cognitive impair

104 Patients with remitted major depressive disorder (MDD) were previously

105 executive dysfunction in partially or fully remitted major depressive disorder (MDD).

106 progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects, with incr

107 f how and why recurrent, unprovoked seizures remit may further our understanding and treatment of epi

108 jects were divided into current MDD (N=882), remitted MDD (N=635) and control (N=331) groups.

109 A total of 63 medication-free remitted MDD (rMDD) patients (33 melancholic and 30 nonm

110 5 psychotropic medication-free patients with remitted MDD and no relevant comorbidity.

111 f past exposure to depression, as those with remitted MDD had shorter TL than controls.

112 ciodemographic-adjusted TL was shorter among remitted MDD patients (mean bp=5459; P=0.014) and curren

113 n of an fMRI signature of recurrence risk in remitted MDD.

114 This study investigated whether remitted melancholic MDD patients, who are at an elevate

115 dentified: never/infrequent, preschool-onset remitting, midchildhood-onset remitting, school age-onse

116 proves the functional outcome in a relapsing/remitting model of experimental autoimmune encephalomyel

117 c imaging data in 46 patients with relapsing-remitting MS (median disease duration, 0.8 year) were an

118 Case series of patients with relapsing-remitting MS (n = 123) or secondary-progressive MS (n =

119 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8) were incl

120 is reduced in CD4(+) T cells from relapsing-remitting MS (RR-MS) patients during relapse.

121 comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that of age- an

122 Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS

123 progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched healthy con

124 of plaques in acute monophasic and relapsing-remitting MS (RRMS) were active.

125 ses followed by remissions, called relapsing-remitting MS (RRMS).

126 solated syndrome (CIS) and 69 with relapsing-remitting MS (RRMS; mean age: CIS: 31.4 +/- 9.0; RRMS: 3

127 sive MS (r = 0.67; p < 0.001) than relapsing-remitting MS (RRMS; r = 0.33; p = 0.007).

128 itting MS multiple sclerosis ( RRMS relaxing-remitting MS ) patients, and 12 secondary progressive MS

129 ary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers, genetica

130 ers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive MS [SPMS],

131 ospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive MS, 61 pa

132 Eighteen patients with relapsing-remitting MS and 17 healthy controls were cognitively as

133 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects underwent a

134 Forty-eight patients with relapsing-remitting MS and 24 control subjects underwent multimoda

135 ty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched control partici

136 Twenty-six patients with relapsing-remitting MS and 32 healthy control subjects from four c

137 One hundred patients with relapsing-remitting MS and 50 healthy controls.

138 of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prospective fol

139 tatus Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status Scale sco

140 were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based morphometry

141 xplain IPS and EF in patients with relapsing-remitting MS and confirms the central role of the thalam

142 3.4 yrs) with clinically definite, relapsing-remitting MS and mild disability (EDSS - Expanded Disabi

143 nformed consent, six patients with relapsing-remitting MS and six healthy control subjects underwent

144 Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing primary-prog

145 erformance of 99 clinically stable relapsing-remitting MS for whom data from four consequent clinical

146 t study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 patients with

147 atients with clinically definitive relapsing-remitting MS in comparison with healthy control subjects

148 ive MS was reduced relative to RRMS relaxing-remitting MS in WM white matter , GM gray matter , and l

149 4 healthy control participants, 18 relapsing-remitting MS multiple sclerosis ( RRMS relaxing-remittin

150 RRMS relaxing-remitting MS patients had lower WM white matter and GM g

151 data from a large cohort of 1,697 relapsing-remitting MS patients in British Columbia, Canada (1995-

152 Ten relapsing-remitting MS patients were studied using the TSPO radiol

153 Relapsing-remitting MS patients who developed PML under NTZ therap

154 Data on 201 pregnant women with relapsing-remitting MS were collected prospectively from January 1

155 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in these studi

156 Additionally, patients with relapsing-remitting MS were treated with narrowband UVB photothera

157 articipants included patients with relapsing-remitting MS who were switching therapy to fingolimod or

158 peripheral blood of patients with relapsing-remitting MS with a high disease score.

159 nically isolated syndrome [CIS] or relapsing-remitting MS) and were also compared to two other popula

160 nically isolated syndrome (CIS) or relapsing-remitting MS, as well as for 15 age- and sex-matched con

161 Among patients with relapsing-remitting MS, nonmyeloablative hematopoietic stem cell t

162 le in the inflammatory response in relapsing-remitting MS.

163 ame doses shown to be effective in relapsing-remitting MS.

164 ecline in a group of subjects with relapsing-remitting MS.

165 sening of disease in patients with relapsing-remitting MS.

166 174 relapsing-remitting MS/CIS patients were included in this analysis

167 isease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years disease durati

168 Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expa

169 secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -0.29 and -

170 th clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disability Status

171 topoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an ongoing, mu

172 e of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the o

173 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients have comparab

174 ions and disease progression among relapsing-remitting multiple sclerosis (MS) patients in the "real-

175 Patients who develop relapsing-remitting multiple sclerosis (MS) present with a first c

176 No current therapy for relapsing-remitting multiple sclerosis (MS) results in significant

177 herapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).

178 RI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

179 inically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive mul

180 esion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-ab NMOSD pa

181 f processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other inflammato

182 ation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of altered i

183 rebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have higher replacem

184 newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in

185 rculating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients and healthy

186 ly showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients exhibited e

187 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are sta

188 is (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laquinimod slo

189 ) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS).

190 ith long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).

191 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

192 n used as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS).

193 Participants were patients with relapsing-remitting multiple sclerosis 18 to 55 years old with at

194 Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety and Effica

195 nterferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and Internation

196 the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the

197 cts on disability in patients with relapsing-remitting multiple sclerosis are maintained and cost eff

198 es in the outer cord were lower in relapsing-remitting multiple sclerosis compared with clinically is

199 omparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the UK RSS with

200 study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or di

201 ients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres in Europe a

202 m propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six oth

203 e multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these reductions

204 gulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no efficacy

205 ellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 heathy cont

206 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using multiparamet

207 Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence on diseas

208 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP,

209 d interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.

210 um IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured using the now

211 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1

212 ight be an effective treatment for relapsing-remitting multiple sclerosis with less frequent administ

213 f CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neurological ex

214 atients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had completed the SELE

215 with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple s

216 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of PML, were

217 rferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative

218 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed effi

219 teria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one of the stu

220 As treatment for relapsing-remitting multiple sclerosis, glatiramer acetate generic

221 underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accumulation o

222 e so in secondary progressive than relapsing remitting multiple sclerosis, tissue structural abnormal

223 n her late 30s with a diagnosis of relapsing-remitting multiple sclerosis, who continued to accumulat

224 tients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0.5 m

225 oral therapy for the treatment of relapsing remitting multiple sclerosis.

226 treatment of people suffering from relapsing-remitting multiple sclerosis.

227 mAb approved for the treatment of relapsing-remitting multiple sclerosis.

228 cts on annualised relapse rates in relapsing-remitting multiple sclerosis.

229 for the diagnosis and treatment of relapsing remitting multiple sclerosis.

230 st widely prescribed treatment for relapsing remitting multiple sclerosis.

231 between secondary progressive and relapsing remitting multiple sclerosis.

232 Treg homeostasis in patients with relapsing-remitting multiple sclerosis.

233 oved for treatment of relapsing or relapsing-remitting multiple sclerosis.

234 in the management of patients with relapsing-remitting multiple sclerosis.

235 on relapse rates in patients with relapsing-remitting multiple sclerosis.

236 CE trial, a study of patients with relapsing-remitting multiple sclerosis.

237 disease activity in patients with relapsing-remitting multiple sclerosis.

238 stration approved for treatment of relapsing-remitting multiple sclerosis.

239 prognostic factor in patients with relapsing-remitting multiple sclerosis.

240 cy of amiselimod in patients with relapsing- remitting multiple sclerosis.

241 a-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

242 to adverse events in patients with relapsing-remitting multiple sclerosis?

243 iated with the atypical MDD subtype both for remitted (n = 144, odds ratio = 1.53, 95% confidence int

244 ssion and Anxiety with current (n = 1062) or remitted (n = 711) MDD and healthy control subjects (n =

245 hosis (n=12), compared with UHR subjects who remitted (n=41) and healthy controls (n=54).

246 il now, this reaction has been primarily the remit of noble-metal catalysts, despite extensive work s

247 Women who remitted on antipsychotic monotherapy were advised to co

248 wheezing is common, but predicting who will remit or have persistent childhood asthma remains diffic

249 ifferences as a function of state (depressed/remitted) or number of previous episodes.

250 occurrence of spontaneous seizures naturally remits over time without any therapeutic intervention.

251 The remitted patients and combat controls did not differ on

252 response to negative pictures compared with remitted patients and combat controls.

253 ic patients could also be discriminated from remitted patients based on clinical characteristics (acc

254 Remitted patients with major depressive disorder (rMDD)

255 on of antidepressant users and proportion of remitted patients, and methodological characteristics di

256 sing were compared between the three groups (remitted patients, N=21; persistent patients, N=22; and

257 response to negative pictures compared with remitted patients.

258 cortices was reduced in both persistent and remitted patients.

259 ected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

260 white matter lesion enlargement in relapsing remitting patients and is associated with greater brain

261 ents are immunologically closer to relapsing-remitting patients as compared with patients with primar

262 urine samples from a cohort of 70 relapsing-remitting patients with MS who were followed for 2 years

263 e-modifying agents for its initial relapsing-remitting phase, these therapies show limited efficacy i

264 Effects of remitted psychiatric disorders on the risk of suicide at

265 ere higher than both combat controls and the remitted PTSD group.

266 Across adult life, CMH followed a dynamic remitting-relapsing course.

267 Patients with stable IHD enrolled in the REMIT (Responses of Mental Stress-Induced Myocardial Isc

268 linically isolated syndrome (CIS), relapsing remitting (RR) and secondary progressive (SP) MS.

269 e investigated this in people with relapsing-remitting (RR) and secondary progressive (SP) MS.

270 matched normal controls (NC), and relapsing-remitting (RR) MS patients, also matched with RIS for br

271 nalysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS patients and

272 Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive appro

273 Among 806 patients with relapsing remitting (RR) onset MS from the London Ontario database

274 re measured by ELISA in cases with relapsing-remitting (RR)-MS (n=81), secondary progressive (SP) MS

275 reschool-onset remitting, midchildhood-onset remitting, school age-onset persisting, late childhood-o

276 presents a case of a patient with relapsing-remitting severe BBE.

277 an treatments within one week from the onset remitted shortly.

278 stent MDD effects, regardless of episodes or remitted state, namely on proteomic measures related to

279 In the remitted state, only patients with BD showed impaired em

280 y compared during the depressed, but not the remitted, state, while state might potentially modulate

281 stinguish clinically during the depressed or remitted states.

282 was not observed in MDD women, despite their remitted status, suggesting that dysregulation of gonada

283 ery is one of the few interventions that can remit T2D.

284 : Adult participants (persistent ADHD, N=35; remit-ted ADHD, N=47; never affected, N=99) were scanned

285 Among those who remitted, the mean decrease in HAM-D score was 24.7 poin

286 The project has evolved from its original remit to collect and integrate all data for a single spe

287 ificantly less likely than those who did not remit to develop a new SUD (13.1% vs 27.2%, P < .001).

288 t; however, only about one-third of patients remit to single-modality treatments with no meaningful d

289 rting the acute phase, 70% responded and 47% remitted to acute ECT.

290 ata, and superior longitudinal fasciculus in remitted vs persistent PTSD patients.

291 8 MS patients (9 progressive and 9 relapsing-remitting) was compared to healthy controls and underwen

292 ntelligence with lifetime disorders that had remitted were attenuated compared with past-year disorde

293 se 2 (reported separately), patients who had remitted were randomly assigned to receive pharmacothera

294 Midchildhood-onset (4(1/2) years) remitting wheeze was associated with BDR (OR, 1.77; 95%

295 Preschool-onset (18 months) remitting wheeze was only associated with FEV1/FVC ratio

296 der and whose major depression had failed to remit with venlafaxine hydrochloride monotherapy, 91 rec

297 tment trials, were contrasted with those who remitted with a first treatment trial.

298 which mice develop spontaneous seizures that remit within 1 month.

299 ovide insights into why spontaneous seizures remit without anticonvulsant treatment.

300 epilepsy with recurrent, unprovoked seizures remitting without any intervention.